Q3 2026 IVD Market Insights
Share this article:
Core Lab, Molecular Dx & Microbiology / Specialty Dx
By James Garvin, IVD Practice Leader & Sr. Consultant | Ensolve Research | November 2026
The third quarter of 2026 separated the in vitro diagnostics market along new lines. In core lab, China's pricing reform did more to sort winners from laggards than any product launch. In molecular diagnostics, growth came almost entirely from outside respiratory testing. In specialty diagnostics, microbiology and pathology, the quarter's biggest stories were about who owns what: a private equity takeover, a divestiture, a carve-out and two pathology acquisitions.
Our Q3 2026 IVD Market Insights report covers 19 business units across 13 publicly traded IVD companies. Five themes stood out:
1 . China pricing reform split the core lab field. Vendors with strong businesses outside China grew; China-exposed vendors declined.
2. Alzheimer's blood testing reached core lab analyzers. Roche's Elecsys pTau217 won the first FDA clearance for a single-biomarker blood test for amyloid rule-in and rule-out.
3. Molecular growth moved outside respiratory. Non-respiratory syndromic panels, sexual health and GI testing offset a weak respiratory season.
4. Near-patient molecular testing kept expanding. bioMérieux placed more than 900 SPOTFIRE systems in the quarter, and new competitors are targeting the same accounts.
5.
A wave of ownership and portfolio changes.
EQT agreed to acquire QIAGEN, Thermo Fisher sold its microbiology business, Siemens began carving out Olyrian Diagnostics, and Roche and Leica both expanded in pathology.
All revenue figures are for each company's IVD business unit, converted to U.S. dollars at Q3 average exchange rates, with growth on the basis each company reports.
Core lab demand held up in the third quarter, but finalized national IVD pricing guidelines and provincial testing-price revisions in China cut multinational sales there. The result was a clear divide. Roche's Core Lab grew 7% (CER) to $2.5B, and 9% over nine months excluding China, while Roche Diagnostics' China sales fell 13% year to date. Abbott's Core Laboratory business grew 5.4% to $1.4B, with balanced growth across the U.S., Europe, Japan and Latin America. Beckman Coulter posted its best organic growth quarter in more than two years, with Danaher pointing to DxI 9000 traction and easing China policy headwinds.
Sysmex delivered $892M in July–September revenue, up 12.1% in yen (a figure that includes a weak-yen boost); first-half revenue grew 8.3% excluding currency effects, led by hematology installations in the Americas (+16.5%). Its China sales fell 22.4% in the first half, and Sysmex has flagged further testing-price revisions from early 2027.
At the other end, QuidelOrtho's Labs revenue fell 5.9% in constant currency to $353M as China Labs revenue dropped 45.5%. Outside China, Labs grew 3.8%. Siemens Healthineers' Diagnostics revenue fell 4.2% on a comparable basis to $1.24B in its fiscal fourth quarter.
Alzheimer's blood testing reaches the core lab
The quarter's most significant core lab launch was neurological. Roche's Elecsys pTau217 became the first FDA-cleared single-biomarker blood test for ruling amyloid pathology in or out, and it runs on more than 4,500 cobas instruments already installed in the U.S. Beckman Coulter's Access p-Tau217 received CE marking under IVDR in July, while Abbott's assay for Alinity remains in development with ALZpath. Neurology menus are becoming a visible point of difference in immunoassay competition.
Restructuring and carve-outs
Two core lab vendors are reorganizing. Siemens Healthineers began carving out its diagnostics business as Olyrian Diagnostics, to become standalone by mid-2028 and announced a five-year extension of its relationship with Quest Diagnostics. QuidelOrtho announced a cost transformation and restructuring program targeting more than $80M in 2027 savings. Customers of both are likely to weigh these changes at contract renewal.
| Business unit | Q3 revenue | Growth | Ensolve tier (vs. Q2) |
Q3 headline |
|---|---|---|---|---|
| Roche Core Lab | $2.5B | +7.0% CER | Leader ↑ | Elecsys pTau217 FDA-cleared |
| Sysmex | $892M | +12.1% (yen, incl. FX) | Leader → | Americas hematology growth; FY forecast raised |
| Beckman Coulter | Not disclosed |
Best organic growth in 2+ years | Leader ↑ | DxU 1800 launch; DxI 9000 traction |
| Abbott Core Lab | $1.4B | +5.4% comparable |
Resilient → | Balanced regional growth |
| Siemens Healthineers Dx | $1.24B | -4.2% comparable |
Restructuring → | Olyrian carve-out; Quest extension |
| QuidelOrtho Labs | $353M | -5.9% CC | Restructuring ↓ | China Labs -45.5%; >$80M restructuring |
Download the Full Q3 2026 IVD Market Insights Presentation
VOC management quotes · Competitive snapshots by segment · Customer research questions
Molecular Diagnostics: Growth Moves Outside Respiratory
A soft respiratory season weighed on every molecular vendor with a large respiratory business, and growth came from everything else. bioMérieux's Molecular Biology revenue grew 8.7% (CER) to $476M, with non-respiratory BIOFIRE panels up 25% while respiratory panels fell 8%. Cepheid's non-respiratory business grew at a low double-digit rate, led by Group A strep, virology and sexual health, while its respiratory revenue declined to about $350M. Diasorin's Molecular revenue grew 11% to $59M on 36% growth in automated multiplex testing; its LIAISON PLEX platform reached about 170 U.S. customers, most of them choosing customizable Flex panels, and its GI panel launched in the U.S. in July.
Roche's Molecular Lab grew 4.0% to $800M, helped by 17% nine-month growth in transplant testing and the CE-market launch of cobas HDV for hepatitis D. Abbott's Rapid/Molecular Diagnostics line, which combines rapid, molecular and point-of-care testing, grew 0.9% to $899M and is down 5.4% over nine months. Abbott's growth in diagnostics is coming from Cancer Diagnostics instead, where Cologuard drove 13.8% comparable growth and SimpleScreen CRC, a blood-based colorectal cancer screening test, launched on September 30.
bioMérieux placed more than 900 SPOTFIRE systems in the quarter, bringing the installed base to about 8,200, and SPOTFIRE revenue grew 20.5%. Shortly after the quarter, on October 22, the SPOTFIRE Vaginitis Panel received FDA clearance and CLIA waiver, taking the platform into women's health ahead of a U.S. launch in early 2027. Competition for these accounts is growing: Cepheid's 13-pathogen Xpert Respiratory Panel was FDA-cleared on September 29, and Diasorin is launching its LIAISON NES point-of-care system through McKesson.
| Business unit | Q3 revenue | Growth | Ensolve tier (vs. Q2) |
Q3 headline |
|---|---|---|---|---|
| bioMérieux Molecular | $476M | +8.7% CER | Leader ↑ | 900+ SPOTFIRE placements; non-resp panels +25% |
| Diasorin Molecular | $59M | +11% CER | Leader NEW | Automated multiplex +36%; PLEX GI launch |
| Cepheid (Danaher) | Not disclosed |
Non-resp +low double digits |
Resilient → | 13-pathogen Xpert Respiratory Panel cleared |
| Roche Molecular Lab | $800M | +4.0% CER | Resilient → | cobas HDV launch; AXELIOS orders |
| Abbott Rapid/Molecular | $899M | +0.9% comparable |
Under Pressure New scope |
Flat quarter after a 9M decline |
Download the Full Q3 2026 IVD Market Insights Presentation
VOC management quotes · Competitive snapshots by segment · Customer research questions
Specialty Dx, Microbiology and Pathology: Ownership Changes Reshape the Segment
No segment changed hands as much as this one. EQT agreed on October 21 to acquire QIAGEN in a deal valued at about $12.1B, and QIAGEN cancelled its Q3 earnings call and suspended guidance. Thermo Fisher completed the $1.075B sale of its microbiology business to Astorg in August; the business will relaunch under a new brand. In pathology, Roche's acquisition of PathAI ($750M upfront) is expected to close in the second half of 2026, and Leica Biosystems closed its acquisition of StatLab on September 28. Bio-Rad began an $80–90M restructuring with activist Elliott Management engaged, and Bruker made Microbiology and Infection Diagnostics a standalone reportable segment.
Growth concentrated in a few places. Roche Pathology grew 8% to $585M, with companion diagnostics up 21% over nine months. bioMérieux's Microbiology business grew 8.4% to $426M on VITEK and BACT/ALERT, with China stabilizing. Diasorin's Immunodiagnostics business grew 5% to $247M, led by its hypertension panel and European TB testing, each up more than 20%. Most other vendors grew between 0% and 3%: Waters' Advanced Diagnostics (+2.0%, as it launched the BACTEC FXi blood culture system), Bruker's BMID (+2.6% reported), QIAGEN's Diagnostic Solutions (+1%), Bio-Rad's Clinical Diagnostics (+2.8%) and Thermo Fisher's Specialty Diagnostics (flat organically).
Rapid sepsis diagnostics drew investment from several directions. QIAGEN completed its QIAstat-Dx bloodstream infection menu, with both panels now FDA-cleared and CE-IVDR certified, covering 33 pathogen targets and 28 resistance markers. Waters commercialized BACTEC FXi, and Bruker acquired the DISQVER blood-based metagenomic sequencing platform, which is currently for research use only. Blood culture, rapid identification panels and sequencing are now competing for a place in the same workflow.
| Business unit | Q3 revenue | Growth | Ensolve tier (vs. Q2) |
Q3 headline |
|---|---|---|---|---|
| Roche Pathology | $585M | +8.0% CER | Leader → | Companion Dx +21% (9M); PathAI pending |
| bioMérieux Microbiology | $426M | +8.4% CER | Leader ↑ | VITEK and BACT/ALERT growth; China stable |
| Waters Advanced Diagnostics |
$575M | +2.0% | Resilient ↓ | BACTEC FXi and Onclarity self-collection launched |
| Diasorin Immunodiagnostics |
$247M | +5% CER | Resilient NEW | Hypertension and Europe TB each >20% |
| Bruker BMID | $134M | +2.6% reported | Under Pressure ↓ |
Acquired DISQVER mNGS platform |
| QIAGEN Diagnostic Solutions |
$209M | +1% CER | Under Pressure → |
EQT takeover agreed (post-quarter) |
| Thermo Fisher Specialty Dx |
$1.10B | Flat organic | Under Pressure ↑ |
Microbiology sold to Astorg |
| Bio-Rad Clinical Diagnostics |
$402M | +2.8% CN | Restructuring → | $80–90M restructuring; Elliott engaged |
Bruker BMID growth is reported and includes the DISQVER acquisition. CN = currency-neutral.
Download the Full Q3 2026 IVD Market Insights Presentation
VOC management quotes · Competitive snapshots by segment · Customer research questions
Work with Ensolve Research
Ensolve Research is a MedTech marketing research consultancy specializing in the IVD and medical technology industries. We design and execute primary research that translates market signals into actionable marketing & commercial intelligence.
Our 2026 IVD research capabilities include:
- Global VOC Studies — Structured interviews and surveys with lab directors, clinical scientists, and procurement leaders across US, EMEA, and APAC
- Pricing Research — Conjoint analysis, willingness-to-pay, and price elasticity studies for novel assay and platform launches
- Platform Displacement Research — Identifying the specific triggers that cause lab directors to switch platforms
- Sample Journey & Workflow Mapping — Ethnographic research into clinical diagnostic workflows to identify unmet needs
- Concept & Messaging Optimization — Pre-launch testing of clinical claims and value propositions with target buyer segments
- Competitive Wargaming — Structured research-based competitive positioning studies for platform launch strategy
If your team is evaluating a platform launch, menu expansion, or competitive displacement strategy in 2027, these questions are not theoretical — they are commercial decisions.
Ensolve Research designs VOC research to answer them before launch.
Ensolve Research publishes quarterly IVD Market Intelligence Reports synthesizing earnings data from the industry's leading diagnostic companies. This analysis covers Q3 2026.

About the Author — James Garvin
Senior Consultant
James Garvin, IVD Practice Leader & Sr. Consultant, partners with the world's leading IVD manufacturers to translate Voice of Customer and market intelligence into winning commercial strategies across product development, pricing, and positioning. James previously served as Director of Product Management at Beckman Coulter and led global commercial operations at Thermo Fisher Scientific.




